NewsBenzingaGSK conferma una guidance per l’EPS rettificato FY2026 di $4,90-$5,00 rispetto a una stima di $4,78; conferma una guidance per le vendite FY2026 di $44,754 miliardi rispetto a una stima di $45,150 miliardi GSK conferma una guidance per l’EPS rettificato FY2026 di $4,90-$5,00 rispetto a una stima di $4,78; conferma una guidance per le vendite FY2026 di $44,754 miliardi rispetto a una stima di $45,150 miliardi Benzinga 2026.10.28 07:58 (GMT+0) Open on Benzinga Other news Tether-Backed Stablecoin USA₮ Goes Live on Avalanche Billionaire Charlie Munger Called Robinhood ‘A Gambling Parlor Masquerading As a Respectable Business’ and Now They Hold 70 Million Trump Accounts A Strong Q3 Puts Nvidia (NVDA) Stock on Track for a Quick 194% Options Payout As Netflix Stock Hovers Near Its 52-Week Low, Analyst Sentiment Remains Mixed. Here's Why. How to Play General Motors Stock as GM Shares Switch to the Nasdaq British hackers face prison for GTA 6 data breach and crypto thefts
Billionaire Charlie Munger Called Robinhood ‘A Gambling Parlor Masquerading As a Respectable Business’ and Now They Hold 70 Million Trump Accounts